Core Viewpoint - Veradermics has announced the pricing of its upsized initial public offering (IPO) of 15,077,647 shares at $17.00 per share, aiming to raise approximately $256.3 million before expenses [1] Company Overview - Veradermics is a late clinical-stage biopharmaceutical company founded by dermatologists, focusing on innovative therapeutics for aesthetic and dermatological conditions [1] - The company is developing a focused portfolio of aesthetic dermatology product candidates, with a lead program, VDPHL01, targeting pattern hair loss [1] Initial Public Offering Details - The IPO is set to close on February 5, 2026, subject to customary closing conditions, with trading on the New York Stock Exchange expected to begin on February 4, 2026, under the ticker symbol "MANE" [1] - The underwriters have a 30-day option to purchase an additional 2,261,647 shares at the IPO price [1] Product Development - VDPHL01 is being developed as an oral, non-hormonal treatment for pattern hair loss, designed to enhance the effectiveness of minoxidil while minimizing cardiac risks [1] - The company has completed enrollment in its Phase 2/3 clinical trial for VDPHL01 for male pattern hair loss and is actively enrolling women for the first oral treatment trial for female pattern hair loss [2]
Veradermics Announces Pricing of Upsized Initial Public Offering